Related Experiment Video
Updated: Apr 29, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Secondary prevention of coronary artery disease with lipid-lowering drugs]
1Service de Cardiologie, Hôpital Cardiovasculaire et Pneumologique Louis-Pradel, BP Lyon Montchat, 69394 Lyon Cedex 3. francois.delahaye@chu-lyon.fr
Insights
Statins significantly reduce cardiovascular events and all-cause mortality in coronary patients. These cholesterol-lowering drugs are recommended as a first-line treatment for heart disease.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Cardiovascular disease remains a leading cause of mortality worldwide.
- Before statins, hypolipidemic drugs like fibrates showed limited impact on overall mortality.
- The efficacy of lipid-lowering therapies on cardiovascular outcomes was a significant clinical question.
Purpose:
- To evaluate the impact of statins on cardiovascular morbidity, mortality, and total mortality.
- To review the role of statins as a first-line treatment for coronary patients.
- To discuss the potential benefits of targeting HDL cholesterol and triglycerides.
Summary:
- The 4S study, along with CARE and LIPID trials, demonstrated statins' efficacy in reducing cardiovascular morbidity and mortality.
- Statins are recommended for all coronary patients, aiming for cholesterol levels below 2 g/l.
- While statins are first-line, adjunctive therapies like fibrates or HDL-raising drugs may be considered in specialized settings, alongside lifestyle modifications and risk factor management.
Impact:
- Statins have revolutionized cardiovascular disease management, offering significant reductions in mortality.
- Establishes statins as a cornerstone therapy in cardiology.
- Highlights the ongoing need for comprehensive cardiovascular risk management, including diet and other risk factors.
Abstract:
Before the statins era, this was one of the most debated questions in the field of cardiology: although hypolipidemic drugs (mainly fibrates) decreased the cardiovascular morbidity and mortality, their influence on total mortality was not significant. The 4S study demonstrated the efficacy of a statin on cardiovascular morbidity and mortality and on total mortality. This was confirmed by the CARE and the LIPID trials. Statins should be prescribed to all coronary patients, whatever the type of coronary disease, the age (we do not know yet for people older than 80), the gender, the basal cholesterol level (maybe statins are not efficacious when it is<2g/l); cholesterol level has to be lowered below 2g/l. Two trials of drugs increasing the HDL cholesterol level were recently published. Unfortunately their results are contradictory. Statins should be the first level drugs. Maybe it is useful to decrease the triglycerides level and to increase the HDL cholesterol level. The association of a statin and a fibrate is reserved to specialized centers. We should not forget the usefulness of diet. We must also take the other risk factors into account.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management